Search

Your search keyword '"Pol, Stanislas"' showing total 1,987 results
Start Over Author "Pol, Stanislas"
1,987 results on '"Pol, Stanislas"'

101. PAGE-B and FIB-4 predict the occurence of hepatocellular carcinoma in HBV patients: a french nationwide cohort study

Author

Boillet, Gautier, primary, Chalouni, Mathieu, additional, Lusivka-Nzinga, Clovis, additional, Teoule, François, additional, Fontaine, Helene, additional, Nahon, Pierre, additional, Bourliere, Marc, additional, Carrat, Fabrice, additional, Pol, Stanislas, additional, de Lédinghen, Victor, additional, and Wittkop, Linda, additional

Published
2022
Full Text
View/download PDF

102. Fatty liver index as a risk factor for all-cause and liver related mortality in patients under therapy for chronic hepatitis B (ANRS CO22 Hepather cohort study)

Author

Hermabessiere, Paul, primary, Chalouni, Mathieu, additional, Bourliere, Marc, additional, Nahon, Pierre, additional, Teoule, François, additional, Lusivka-Nzinga, Clovis, additional, Fontaine, Helene, additional, Pol, Stanislas, additional, Carrat, Fabrice, additional, de Lédinghen, Victor, additional, and Wittkop, Linda, additional

Published
2022
Full Text
View/download PDF

103. Diversity of circulating HBV genomes and impact on viral infection

Author

Sotty, Jules, primary, Schnuriger, Aurélie, additional, Bablon, Pierre, additional, Lekbaby, Bouchra, additional, Augustin, Jeremy, additional, Girier-Dufournier, Morgane, additional, Langlois, Lucas, additional, Dorival, Celine, additional, Carrat, Fabrice, additional, Pol, Stanislas, additional, Fontaine, Helene, additional, Sarica, Nazim, additional, Neuveut, Christine, additional, Housset, Chantal, additional, Kremsdorf, Dina, additional, and Soussan, Patrick, additional

Published
2022
Full Text
View/download PDF

105. Role of liver biopsy in management of immune checkpoint inhibitors hepatitis: a single-center retrospective study

Author

Marcin, Kennie, primary, Parlati, Lucia, additional, Terris, Benoit, additional, Hollande, Clemence, additional, Pichard, Anais Vallet, additional, Fontaine, Helene, additional, Cororuge, Marion, additional, Mehiri, Loriane Lair, additional, Mallet, Vincent, additional, Sogni, Philippe, additional, and Pol, Stanislas, additional

Published
2022
Full Text
View/download PDF

106. Liver toxicities of immune checkpoints inhibitors for cancer: a multicenter retrospective study

Author

Parlati, Lucia, primary, Sakka, Mehdi, additional, Bellanger, Agnès, additional, Meritet, Jean François, additional, Bouam, Samir, additional, Retbi, Aurelia, additional, Rufat, Pierre, additional, Bonnefont-Rousselot, Dominique, additional, Batista, Rui, additional, Tilleul, Patrick, additional, Thabut, Dominique, additional, Spano, Jean-Philippe, additional, Goldwasser, Francois, additional, Sogni, Philippe, additional, Pol, Stanislas, additional, and Mallet, Vincent, additional

Published
2022
Full Text
View/download PDF

107. Overall mortality in patients with chronic hepatitis C: major effects of social vulnerability, tobacco smoking, and history of unhealthy alcohol use (ANRS CO22 HEPATHER cohort)

Author

Perieres, Lauren, primary, Carrat, Fabrice, additional, Lotto, Marta, additional, Dorival, Celine, additional, Ramier, Clémence, additional, Marcellin, Fabienne, additional, Cagnot, Carole, additional, Delarocque-Astagneau, Elizabeth, additional, Carrieri, Patrizia, additional, Pol, Stanislas, additional, Fontaine, Helene, additional, and Protopopescu, Camelia, additional

Published
2022
Full Text
View/download PDF

109. Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers

Author

Lam, Laurent, primary, Fontaine, Helene, additional, Lapidus, Nathanaël, additional, Dorival, Celine, additional, Bellet, Jonathan, additional, Larrey, Dominique, additional, Nahon, Pierre, additional, Diallo, Alpha, additional, Cagnot, Carole, additional, Lusivka-Nzinga, Clovis, additional, Teoule, François, additional, Hejblum, Gilles, additional, Bourliere, Marc, additional, Pol, Stanislas, additional, and Carrat, Fabrice, additional

Published
2022
Full Text
View/download PDF

110. Biologic targeted therapies in pediatric rheumatology

Author

Guillaume-Czitrom, Séverine, Bachelez, Hervé, Berthelot, Jean-Marie, Bouhnik, Yoram, Bruckert, Eric, Claudepierre, Pascal, Constantin, Arnaud, de Bandt, Michel, Fautrel, Bruno, Gaudin, Philippe, Goëb, Vincent, Gossec, Laure, Gottenberg, Jacques-Eric, Goupille, Philippe, Hachulla, Eric, Huet, Isabelle, Jullien, Denis, Launay, Odile, Lemannf, Marc, Lequerré, Thierry, Maillefert, Jean-Francis, Mariette, Xavier, Marolleau, Jean-Pierre, Martinez, Valérie, Masson, Charles, Morel, Jacques, Mouthon, Luc, Pham, Thao, Pol, Stanislas, Puéchal, Xavier, Richette, Pascal, Saraux, Alain, Schaeverbeke, Thierry, Sellam, Jérémie, Blacher, Jacques, Soubrier, Martin, Sudre, Anne, Viguier, Manuelle, Vittecoq, Olivier, Wendling, Daniel, and Sibilia, Jean

Published
2014
Full Text
View/download PDF

111. Tenofovir Versus Placebo to Prevent Perinatal Transmission of Hepatitis B

Author

Jourdain, Gonzague, Ngo-Giang-Huong, Nicole, Harrison, Linda, Decker, Luc, Khamduang, Woottichai, Tierney, Camlin, Salvadori, Nicolas, Cressey, Tim R., Sirirungsi, Wasna, Achalapong, Jullapong, Yuthavisuthi, Prapap, Kanjanavikai, Prateep, Na Ayudhaya, Orada P., Siriwachirachai, Thitiporn, Prommas, Sinart, Sabsanong, Prapan, Limtrakul, Aram, Varadisai, Supang, Putiyanun, Chaiwat, Suriyachai, Pornnapa, Liampongsabuddhi, Prateung, Sangsawang, Suraphan, Matanasarawut, Wanmanee, Buranabanjasatean, Sudanee, Puernngooluerm, Pichit, Bowonwatanuwong, Chureeratana, Puthanakit, Thanyawee, Klinbuayaem, Virat, Thongsawat, Satawat, Thanprasertsuk, Sombat, Siberry, George K., Watts, Diane H., Chakhtoura, Nahida, Murphy, Trudy V., Nelson, Noele P., Chung, Raymond T., Pol, Stanislas, and Chotivanich, Nantasak

Published
2018
Full Text
View/download PDF

114. The HepHIV 2017 Conference in Malta: joining forces for the earlier diagnosis of HIV and viral hepatitis

Author

Raben, D, Hoekstra, M, Sperle, I, Amato Gauci, AJ, Gauci, C, West, B, Sullivan, A, Lazarus, JV, Platteau, T, Rockstroh, JK, von Lingen, Ann‐Isabelle, Schatz, Eberhard, Godfrey, Fiona, Galea, George, Lundgren, Jens D, de Wit, John, Maistat, Ludmila, Donoghoe, Martin, Kaye, Per, Damme, Pierre, Mauss, Stefan, Reic, Tatjana, Zuilhof, Wim, Casabona, ordi, Dedes, Nikos, Delpech, alerie, Gatell, osé, Gazzard, Brian, Matičič, Mojca, Pol, Stanislas, Sönnerborg, Anders, and Tsereteli, Nino

Published
2018
Full Text
View/download PDF

115. Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Author

Zeuzem, Stefan, Foster, Graham R., Wang, Stanley, Asatryan, Armen, Gane, Edward, Feld, Jordan J., Asselah, Tarik, Bourlière, Marc, Ruane, Peter J., Wedemeyer, Heiner, Pol, Stanislas, Flisiak, Robert, Poordad, Fred, Chuang, Wan-Long, Stedman, Catherine A., Flamm, Steven, Kwo, Paul, Dore, Gregory J., Sepulveda-Arzola, Gladys, Roberts, Stuart K., Soto-Malave, Ruth, Kaita, Kelly, Puoti, Massimo, Vierling, John, Tam, Edward, Vargas, Hugo E., Bruck, Rafi, Fuster, Francisco, Paik, Seung-Woon, Felizarta, Franco, Kort, Jens, Fu, Bo, Liu, Ran, Ng, Teresa I., Pilot-Matias, Tami, Lin, Chih-Wei, Trinh, Roger, and Mensa, Federico J.

Published
2018
Full Text
View/download PDF

117. Assessment of biopsy‐proven liver fibrosis by two‐dimensional shear wave elastography: An individual patient data‐based meta‐analysis

Author

Herrmann, Eva, de Lédinghen, Victor, Cassinotto, Christophe, Chu, Winnie C.‐W., Leung, Vivian Y.‐F., Ferraioli, Giovanna, Filice, Carlo, Castera, Laurent, Vilgrain, Valérie, Ronot, Maxime, Dumortier, Jérôme, Guibal, Aymeric, Pol, Stanislas, Trebicka, Jonel, Jansen, Christian, Strassburg, Christian, Zheng, Rongqin, Zheng, Jian, Francque, Sven, Vanwolleghem, Thomas, Vonghia, Luisa, Manesis, Emanuel K., Zoumpoulis, Pavlos, Sporea, Ioan, Thiele, Maja, Krag, Aleksander, Cohen‐Bacrie, Claude, Criton, Aline, Gay, Joel, Deffieux, Thomas, and Friedrich‐Rust, Mireen

Published
2018
Full Text
View/download PDF

119. Liver Stiffness by Transient Elastography to Detect Porto‐Sinusoidal Vascular Liver Disease With Portal Hypertension

Author

Elkrief, Laure, Lazareth, Marie, Chevret, Sylvie, Paradis, Valérie, Magaz, Marta, Blaise, Lorraine, Rubbia‐Brandt, Laura, Moga, Lucile, Durand, François, Payancé, Audrey, Plessier, Aurélie, Chaffaut, Cendrine, Valla, Dominique, Malphettes, Marion, Diaz, Alba, Nault, Jean‐Charles, Nahon, Pierre, Audureau, Etienne, Ratziu, Vlad, Castera, Laurent, Garcia Pagan, Juan‐Carlos, Ganne‐Carrie, Nathalie, Rautou, Pierre‐Emmanuel, Marcellin, Patrick, Guyader, Dominique, Pol, Stanislas, Fontaine, Hélène, Larrey, Dominique, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Roulot, Dominique, Tran, Albert, Bronowicki, Jean‐Pierre, Zarski, Jean‐Pierre, Leroy, Vincent, Riachi, Ghassan, Calès, Paul, Péron, Jean‐Marie, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Dharancy, Sebastien, Blanc, Jean‐Frédéric, Abergel Olivier Chazouillères, Armand, Mallat, Ariane, Grangé, Jean‐Didier, Attali, Pierre, Bacq, Yannick, Wartelle, Claire, Dao, Thông, Thabut, Dominique, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Nguyen‐Khac, Eric, Bernard‐Chabert, Brigitte, Zucman, David, and Di Martino, Vincent

Subjects
0301 basic medicine, medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Hepatitis C virus, Fatty liver, medicine.disease, medicine.disease_cause, Gastroenterology, 03 medical and health sciences, Liver disease, 030104 developmental biology, 0302 clinical medicine, Esophageal varices, Internal medicine, Ascites, medicine, Portal hypertension, 030211 gastroenterology & hepatology, medicine.symptom, Transient elastography, business
Abstract

Background & aims Porto-sinusoidal vascular liver disease (PSVD) is a rare cause of portal hypertension. PSVD is still often misdiagnosed as cirrhosis, emphasizing the need to improve PSVD diagnosis strategies. Data on liver stiffness measurement (TE-LSM) using transient elastography, in PSVD are limited. The aim of this study was to evaluate the accuracy of TE-LSM to discriminate PSVD from cirrhosis in patients with signs of portal hypertension. Approach & results Retrospective multicenter study comparing TE-LSM in patients with PSVD, according to VALDIG criteria, to patients with compensated biopsy-proven cirrhosis related to alcohol (n=117), hepatitis C virus (HCV) infection (n=110) or non-alcoholic fatty liver disease (NAFLD) (n=46). All patients had at least one sign of portal hypertension among gastroesophageal varices, splenomegaly, porto-systemic collaterals, history of ascites or platelet count Conclusions This study including a total of 155 patients with PSVD and 273 patients with cirrhosis demonstrates that TE-LSM 20 kPa, PSVD is highly unlikely.

Published
2021

121. Histological Characteristics and Management of Hepatitis on Immune Checkpoint Inhibitors: A Retrospective Descriptive Study.

Author

Parlati, Lucia, Marcin, Kennie, Terris, Benoit, Vallet-Pichard, Anaïs, Corouge, Marion, Hollande, Clémence, Sogni, Philippe, Mallet, Vincent, and Pol, Stanislas

Subjects
IMMUNE checkpoint inhibitors, LIVER biopsy, HEPATITIS, IPILIMUMAB, UNIVERSITY hospitals, LIVER injuries
Abstract

Background and aims: the side effects of immune checkpoint inhibitors (ICI) pose a problem for the clinical management of cancer patients. There is a lack of knowledge of the value of liver biopsy in patients with ICI-related drug-induced liver injury (ICI-DILI). The aim of this study was to explore the impact of liver biopsy on clinical management and response to corticosteroids, according to histological findings. Methods: We conducted a retrospective, single-center study to evaluate the biochemical, histological and clinical data of 35 patients with ICI-DILI between 2015 and 2021 in a university hospital in France. Results: Of the 35 patients with ICI-DILI (median [interquartile range] age 62 [48–73] years, 40% males) studied, 20 underwent a liver biopsy. There was no difference in the management of ICI-DILI according to liver biopsy in terms of ICI withdrawal, reduction or rechallenge. According to the histological profile, patients with toxic and granulomatous profiles had a better response to corticosteroids, while patients with cholangitic lesions had the worst response. Conclusion: In ICI-DILI, liver biopsy must not delay patient care but may be useful in identifying patients with a cholangitic profile who have a poorer response to corticosteroids. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

122. Impact of direct‐acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers.

Author

Lam, Laurent, Fontaine, Hélène, Lapidus, Nathanael, Dorival, Céline, Bellet, Jonathan, Larrey, Dominique, Nahon, Pierre, Diallo, Alpha, Cagnot, Carole, Lusivika‐Nzinga, Clovis, Téoulé, François, Hejblum, Gilles, Bourlière, Marc, Pol, Stanislas, and Carrat, Fabrice

Abstract

Purpose: The impact of direct‐acting antivirals (DAAs) on extrahepatic complications in chronic hepatitis C (CHC) patients remains poorly described. We estimated the association of DAAs with cardiovascular events and extrahepatic cancers. Methods: The prospective ANRS CO22 HEPATHER cohort was enriched with individual data until December 2018 from the French Health Insurance Database (SNDS). CHC patients were enrolled between August 2012 and December 2015 in 32 French hepatology centers. A total of 8148 CHC adults were selected. Cardiovascular events (stroke, acute coronary syndrome, pulmonary embolism, heart failure, arrhythmias and conduction disorders [ACD], peripheral arterial disease [PAD]) and extrahepatic solid cancers were derived from the SNDS. Associations between DAAs and extrahepatic events were estimated using marginal structural models, with adjustments for clinical confounders. Results: Analyses of 12 905 person‐years of no DAA exposure and 22 326 person‐years following DAA exposure showed a decreased risk of PAD after DAA exposure (hazard ratio [HR], 0.54; 95% CI, 0.33–0.89), a beneficial effect of DAAs on overall cardiovascular outcomes in patients with advanced fibrosis (aHR, 0.58; 95% CI, 0.42–0.79), and an increased risk of ACD (hazard ratio [HR], 1.46; 95% CI, 1.04–2.04), predominant after the first year following DAA initiation. There was no association between DAAs and extrahepatic cancer risk (HR, 1.23; 95% CI, 0.50–3.03). Conclusions: DAAs were not associated with extrahepatic cancer development or reduction. They were associated with a decreased risk of PAD and an increased risk of ACD, supporting long‐term cardiac monitoring after DAA therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

123. Variability of Primary Sjögren's Syndrome Is Driven by Interferon α and Interferon α Blood Levels Are Associated With the Class II HLA–DQ Locus

Author

Trutschel, Diana, Bost, Pierre, Mariette, Xavier, Bondet, Vincent, Llibre, Alba, Posseme, Celine, Charbit, Bruno, Thorball, Christian W., Jonsson, Roland, Lessard, Christopher J., Felten, Renaud, Ng, Wan Fai, Chatenoud, Lucienne, Dumortier, Hélène, Sibilia, Jean, Fellay, Jacques, Brokstad, Karl A., Appel, Silke, Tarn, Jessica R., Quintana‐Murci, Lluis, Mingueneau, Michael, Meyer, Nicolas, Duffy, Darragh, Schwikowski, Benno, Gottenberg, Jacques Eric, Dernis, Emmanuelle, Devauchelle‐Pensec, Valerie, Dieude, Philippe, Dubost, Jean‐Jacques, Fauchais, Anne‐Laure, Goeb, Vincent, Hachulla, Eric, Hatron, Pierre Yves, Larroche, Claire, Le Guern, Véronique, Morel, Jacques, Perdriger, Aleth, Salliot, Carinne, Rist, Stephanie, Saraux, Alain, Vittecoq, Olivier, Nocturne, Gaétane, Ravaud, Philippe, Seror, Raphaèle, Abel, Laurent, Alcover, Andres, Aschard, Hugues, Astrom, Kalla, Bousso, Philippe, Bruhns, Pierre, Cumano, Ana, Demangel, Caroline, Deriano, Ludovic, Di Santo, James, Dromer, Françoise, Eberl, Gérard, Enninga, Jost, Gelpi, Odile, GompertsBoneca, Ivo, Hasan, Milena, Hercberg, Serge, Lantz, Olivier, Leclerc, Claude, Mouquet, Hugo, Pellegrini, Sandra, Pol, Stanislas, Rausell, Antonio, Rogge, Lars, Sakuntabhai, Anavaj, Schwartz, Olivier, Shorte, Spencer, Soumelis, Vassili, Tangy, Frédéric, Tartour, Eric, Toubert, Antoine, Touvier, Mathilde, Ungeheuer, Marie‐Noëlle, Albert, Matthew L., Biomédecine computationelle des systèmes / Computational systems biomedicine, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Universität Zürich [Zürich] = University of Zurich (UZH), Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] (ETH Zürich), Service de Rhumatologie [CHU Bicêtre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Projet NECESSITY (PN), Hôpitaux Universitaires Paris Sud [AP-HP] (HUPS)-Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Immunologie Translationnelle - Translational Immunology lab, Cytometrie et Biomarqueurs – Cytometry and Biomarkers (UTechS CB), Ecole Polytechnique Fédérale de Lausanne (EPFL), Université de Lausanne = University of Lausanne (UNIL), Lausanne University Hospital, University of Bergen (UiB), Oklahoma Medical Research Foundation (OMRF), University of Oklahoma Health Sciences Center (OUHSC), Université de Strasbourg (UNISTRA), Institut de biologie moléculaire et cellulaire (IBMC), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Newcastle University [Newcastle], Newcastle Upon Tyne Hospitals NHS Foundation Trust, Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Immunologie, Immunopathologie et Chimie Thérapeutique (I2CT), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Génétique Evolutive Humaine - Human Evolutionary Genetics, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Biogen Inc. [Cambridge, MA, USA], Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie (ICube), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Supported by the Innovative Medicines Initiative 2 Joint Undertaking (JU) (grant 806975). The JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Unionand the European Federation of Pharmaceutical Industries and Associations. This work was also supported by the National Institutes of Health (National Institute of Arthritis and Musculoskeletal Skin Disease grant R01-AR-065953). The Assessment of Systemic Signs and Evolution in Sjögren’s Syndrome(ASSESS) national multicenter prospective cohort was formed in 2006 with aFrench Ministry of Health grant (Programme Hospitalier de Recherche Clinique 2005 P060228). The ASSESS cohort is promoted by the French Society of Rheumatology and receives research grants from the French Society of Rheumatology. Dr. Gottenberg’s work was supported by Bristol Myers Squibbfor transcriptomic analysis of the ASSESS and Norwegian cohorts and by Geneviève Garnier (Association Française du Syndrome de Gougerot-Sjögrenet des syndromes secs). Drs. Trutschel’s and Schwikowski’s work was supported by Geneviève Garnier (Association Française du Syndrome de Gougerot-Sjögren et des syndromes secs)., Milieu Intérieur Consortium, ASSESS study investigators, and NECESSITY Consortium: Emmanuelle Dernis, Valerie Devauchelle-Pensec, Philippe Dieude, Jean-Jacques Dubost, Anne-Laure Fauchais, Vincent Goeb, Eric Hachulla, Pierre Yves Hatron, Claire Larroche, Véronique Le Guern, Jacques Morel, Aleth Perdriger, Carinne Salliot, Stephanie Rist, Alain Saraux, Jean Sibilia, Olivier Vittecoq, Gaétane Nocturne, Philippe Ravaud, Raphaèle Seror, Laurent Abel, Andres Alcover, Hugues Aschard, Kalla Astrom, Philippe Bousso, Pierre Bruhns, Ana Cumano, Caroline Demangel, Ludovic Deriano, James Di Santo, Françoise Dromer, Gérard Eberl, Jost Enninga, Jacques Fellay, Odile Gelpi, Ivo GompertsBoneca, Milena Hasan, Serge Hercberg, Olivier Lantz, Claude Leclerc, Hugo Mouquet, Sandra Pellegrini, Stanislas Pol, Antonio Rausell, Lars Rogge, Anavaj Sakuntabhai, Olivier Schwartz, Benno Schwikowski, Spencer Shorte, Vassili Soumelis, Frédéric Tangy, Eric Tartour, Antoine Toubert, Mathilde Touvier, Marie-Noëlle Ungeheuer, Matthew L Albert, Darragh Duffy, Lluis Quintana-Murci., European Project: 806975,NECESSITY, Clauss, Isabelle, and NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients - NECESSITY - 0000-00-00 - 0000-00-00 - 806975 - VALID

Subjects
Proteomics, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Sjogren's Syndrome, Rheumatology, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, HLA-DQ Antigens, Immunology, Humans, Interferon-alpha, Immunology and Allergy, Prospective Studies
Abstract

Objective: Primary Sjögren's syndrome (SS) is the second most frequent systemic autoimmune disease, affecting 0.1% of the general population. To characterize the molecular and clinical variabilities among patients with primary SS, we integrated transcriptomic, proteomic, cellular, and genetic data with clinical phenotypes in a cohort of 351 patients with primary SS. Methods: We analyzed blood transcriptomes and genotypes of 351 patients with primary SS who were participants in a multicenter prospective clinical cohort. We replicated the transcriptome analysis in 3 independent cohorts (n = 462 patients). We determined circulating interferon-α (IFNα) and IFNγ protein concentrations using digital single molecular arrays (Simoa). Results: Transcriptome analysis of the prospective cohort showed a strong IFN gene signature in more than half of the patients; this finding was replicated in the 3 independent cohorts. Because gene expression analysis did not discriminate between type I IFN and type II IFN, we used Simoa to demonstrate that the IFN transcriptomic signature was driven by circulating IFNα and not by IFNγ protein levels. IFNα protein levels, detectable in 75% of patients, were significantly associated with clinical and immunologic features of primary SS disease activity at enrollment and with increased frequency of systemic complications over the 5-year follow-up. Genetic analysis revealed a significant association between IFNα protein levels, a major histocompatibility (MHC) class II haplotype, and anti-SSA antibody. Additional cellular analysis revealed that an MHC class II HLA–DQ locus acts through up-regulation of HLA class II molecules on conventional dendritic cells. Conclusion: We identified the predominance of IFNα as a driver of primary SS variability, with IFNα demonstrating an association with HLA gene polymorphisms., Arthritis & Rheumatology, 74 (12), ISSN:2326-5191, ISSN:2326-5205

Published
2022

126. Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

Author

UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Martin, Paul, Awan, Ahmed A., Berenguer, Marina C., Bruchfeld, Annette, Fabrizi, Fabrizio, Goldberg, David S., Jia, Jidong, Kamar, Nassim, Mohamed, Rosmawati, Pessôa, Mário Guimarães, Pol, Stanislas, Sise, Meghan E., Balk, Ethan M., Gordon, Craig E., Adam, Gaelen, Cheung, Michael, Earley, Amy, Jadoul, Michel, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Martin, Paul, Awan, Ahmed A., Berenguer, Marina C., Bruchfeld, Annette, Fabrizi, Fabrizio, Goldberg, David S., Jia, Jidong, Kamar, Nassim, Mohamed, Rosmawati, Pessôa, Mário Guimarães, Pol, Stanislas, Sise, Meghan E., Balk, Ethan M., Gordon, Craig E., Adam, Gaelen, Cheung, Michael, Earley, Amy, and Jadoul, Michel

Published
2022

127. Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response

Author

Azzi, Jessica, primary, Dorival, Céline, additional, Cagnot, Carole, additional, Fontaine, Hélène, additional, Lusivika-Nzinga, Clovis, additional, Leroy, Vincent, additional, De Ledinghen, Victor, additional, Tran, Albert, additional, Zoulim, Fabien, additional, Alric, Laurent, additional, Gournay, Jérôme, additional, Bronowicki, Jean-Pierre, additional, Decaens, Thomas, additional, Riachi, Ghassan, additional, Mikhail, Nabiel, additional, Soliman, Reham, additional, Shiha, Gamal, additional, Pol, Stanislas, additional, Carrat, Fabrice, additional, and Ganne-Carrié, Nathalie, additional

Published
2022
Full Text
View/download PDF

128. 1117-P: High Rate of Histologically Proven NASH and Advanced Fibrosis in Outpatients with Type 2 Diabetes Screened for NAFLD

Author

GAUTIER, JEAN-FRANÇOIS, primary, CASTERA, LAURENT, additional, VIDAL-TRECAN, TIPHAINE, additional, PARADIS, VALERIE, additional, POYNARD, THIERRY, additional, CZERNICHOW, SEBASTIEN, additional, TERRIS, BENOIT, additional, MANCHON, PAULINE, additional, ROULOT, DOMINIQUE, additional, BIHAN, HELENE, additional, JULLA, JEAN-BAPTISTE, additional, LARGER, ETIENNE, additional, POL, STANISLAS, additional, BEDOSSA, PIERRE, additional, LAOUENAN, CEDRIC, additional, and VALLA, DOMINIQUE C., additional

Published
2022
Full Text
View/download PDF

129. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

Author

Howe, Anita Y.M., primary, Rodrigo, Chaturaka, additional, Cunningham, Evan B., additional, Douglas, Mark W., additional, Dietz, Julia, additional, Grebely, Jason, additional, Popping, Stephanie, additional, Sfalcin, Javier Alejandro, additional, Parczewski, Milosz, additional, Sarrazin, Christoph, additional, de Salazar, Adolfo, additional, Fuentes, Ana, additional, Sayan, Murat, additional, Quer, Josep, additional, Kjellin, Midori, additional, Kileng, Hege, additional, Mor, Orna, additional, Lennerstrand, Johan, additional, Fourati, Slim, additional, Di Maio, Velia Chiara, additional, Chulanov, Vladimir, additional, Pawlotsky, Jean-Michel, additional, Harrigan, P. Richard, additional, Ceccherini-Silberstein, Francesca, additional, Garcia, Federico, additional, Martinello, Marianne, additional, Matthews, Gail, additional, Fernando, Fay Fabián, additional, Esteban, Juan I., additional, Müllhaupt, Beat, additional, Wiesch, Julian Schulze zur, additional, Buggisch, Peter, additional, Neumann-Haefelin, Christoph, additional, Berg, Thomas, additional, Berg, Christoph P., additional, Schattenberg, Jörn M., additional, Moreno, Christophe, additional, Stauber, Rudolf, additional, Lloyd, Andrew, additional, Dore, Gregory, additional, Applegate, Tanya, additional, Ignacio, Juan, additional, Garcia-Cehic, Damir, additional, Gregori, Josep, additional, Rodriguez-Frias, Francisco, additional, Rando, Ariadna, additional, Gozlan, Yael, additional, Angelico, Mario, additional, Andreoni, Massimo, additional, Babudieri, Sergio, additional, Bertoli, Ada, additional, Cento, Valeria, additional, Coppola, Nicola, additional, Craxì, Antonio, additional, Paolucci, Stefania, additional, Parruti, Giustino, additional, Pasquazzi, Caterina, additional, Perno, Carlo Federico, additional, Teti, Elisabetta, additional, Vironet, C., additional, Lannergård, Anders, additional, Duberg, Ann-Sofi, additional, Aleman, Soo, additional, Gutteberg, Tore, additional, Soulier, Alexandre, additional, Gourgeon, Aurélie, additional, Chevaliez, Stephane, additional, Pol, Stanislas, additional, Carrat, Fabrice, additional, Salmon, Dominique, additional, Kaiser, Rolf, additional, Knopes, Elena, additional, Gomes, Perpetua, additional, de Kneght, Rob, additional, Rijnders, Bart, additional, Poljak, Mario, additional, Lunar, Maja, additional, Usubillaga, Rafael, additional, Seguin_Devaux, Carole, additional, Tay, Enoch, additional, Wilson, Caroline, additional, Wang, Dao Sen, additional, George, Jacob, additional, Kok, Jen, additional, Pérez, Ana Belén, additional, Chueca, Natalia, additional, García-Deltoro, Miguel, additional, Martínez-Sapiña, Ana María, additional, Lara-Pérez, María Magdalena, additional, García-Bujalance, Silvia, additional, Aldámiz-Echevarría, Teresa, additional, Vera-Méndez, Francisco Jesús, additional, Pineda, Juan Antonio, additional, Casado, Marta, additional, Pascasio, Juan Manuel, additional, Salmerón, Javier, additional, Alados-Arboledas, Juan Carlos, additional, Poyato, Antonio, additional, Téllez, Francisco, additional, Rivero-Juárez, Antonio, additional, Merino, Dolores, additional, Vivancos-Gallego, María Jesús, additional, Rosales-Zábal, José Miguel, additional, Ocete, María Dolores, additional, Simón, Miguel Ángel, additional, Rincón, Pilar, additional, Reus, Sergi, additional, De la Iglesia, Alberto, additional, García-Arata, Isabel, additional, Jiménez, Miguel, additional, Jiménez, Fernando, additional, Hernández-Quero, José, additional, Galera, Carlos, additional, Balghata, Mohamed Omar, additional, Primo, Joaquín, additional, Masiá, Mar, additional, Espinosa, Nuria, additional, Delgado, Marcial, additional, von-Wichmann, Miguel Ángel, additional, Collado, Antonio, additional, Santos, Jesús, additional, Mínguez, Carlos, additional, Díaz-Flores, Felícitas, additional, Fernández, Elisa, additional, Bernal, Enrique, additional, De Juan, José, additional, Antón, José Joaquín, additional, Vélez, Mónica, additional, Aguilera, Antonio, additional, Navarro, Daniel, additional, Arenas, Juan Ignacio, additional, Fernández, Clotilde, additional, Espinosa, María Dolores, additional, Ríos, María José, additional, Alonso, Roberto, additional, Hidalgo, Carmen, additional, Hernández, Rosario, additional, Téllez, María Jesús, additional, Rodríguez, Francisco Javier, additional, Antequera, Pedro, additional, Delgado, Cristina, additional, Martín, Patricia, additional, Crespo, Javier, additional, Becerril, Berta, additional, Pérez, Oscar, additional, García-Herola, Antonio, additional, Montero, José, additional, Freyre, Carolina, additional, Grau, Concepción, additional, Cabezas, Joaquin, additional, Jimenez, Miguel, additional, Rodriguez, Manuel Alberto Macias, additional, Quilez, Cristina, additional, Pardo, Maria Rodriguez, additional, Muñoz-Medina, Leopoldo, additional, and Figueruela, Blanca, additional

Published
2022
Full Text
View/download PDF

137. Additional file 1 of Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

Author

Pageaux, Georges-Philippe, Nzinga, Clovis Lusivika, Ganne, Nathalie, Samuel, Didier, Dorival, C��line, Zoulim, Fabien, Cagnot, Carole, Decaens, Thomas, Thabut, Dominique, Asselah, Tarik, Mathurin, Philippe, Habersetzer, Fran��ois, Bronowicki, Jean-Pierre, Guyader, Dominique, Rosa, Isabelle, Leroy, Vincent, Chazouilleres, Olivier, de Ledinghen, Victor, Bourliere, Marc, Causse, Xavier, Cales, Paul, Metivier, Sophie, Loustaud-Ratti, V��ronique, Riachi, Ghassan, Alric, Laurent, Gelu-Simeon, Moana, Minello, Anne, Gournay, J��r��me, Geist, Claire, Tran, Albert, Abergel, Armand, Portal, Isabelle, d���Alteroche, Louis, Raffi, Fran��ois, Fontaine, H��l��ne, Carrat, Fabrice, and Pol, Stanislas

Abstract

Additional file 1: Table S1. Balance of baseline covariates following IPTW analysis according to DAA exposure. Table S2. Summary of non-liver related deaths by cause. Table S3. Summary of liver related deaths by cause. Table S4. Factors associated with HCC, all-cause mortality, and liver transplant in all 559 patients included for study. Table S5. Characteristics of hepatocellular carcinoma according to DAA exposure. Table S6. Incidence rates of hepatocellular carcinoma, all-cause mortality, liver-related mortality, non-liver-related mortality, and liver transplant in all 559 patients under study according to DAA exposure period and virological response status. Table S7. Incidence rates of hepatocellular carcinoma, all-cause mortality, liver-related mortality, non-liver-related mortality, and liver transplant in all 55 patients with a Meld score>20 or Child-Pugh score C according to DAA exposure period and virological response status.

Published
2022
Full Text
View/download PDF

138. Impact of Direct‐Acting Antiviral Treatment for Hepatitis C on Cardiovascular Diseases and Extrahepatic Cancers

Author

Lam, Laurent, Fontaine, Helene, Nathanael Lapidus, Dorival, Celine, Bellet, Jonathan, Larrey, Dominique, Nahon, Pierre, Diallo, Alpha, Cagnot, Carole, Lusivka-Nzinga, Clovis, Teoule, Francois, Hejblum, Gilles, Bourliere, Marc, Pol, Stanislas, Carrat, Fabrice, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Département d'hépatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Génomique fonctionnelle des tumeurs solides = Functional Genomics of Solid Tumors [CRC] (FunGeST), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), Hôpital Saint-Joseph [Marseille], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Cité (UPCité), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École pratique des hautes études (EPHE), Service de santé publique [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), and Lam, Laurent

Subjects
Hepatology, Epidemiology, Hepatitis C virus, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.CAN]Life Sciences [q-bio]/Cancer, SNDS, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Oral direct antiviral agents, Adverse events, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Extrahepatic manifestations, Pharmacology (medical), [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Abstract

International audience; Purpose: The impact of direct-acting antivirals (DAAs) on extrahepatic complications in chronic hepatitis C (CHC) patients remains poorly described. We estimated the association of DAAs with cardiovascular events and extrahepatic cancers.Methods: The prospective ANRS CO22 HEPATHER cohort was enriched with individual data until December 2018 from the French Health Insurance Database (SNDS). CHC patients were enrolled between August 2012 and December 2015 in 32 French hepatology centers. A total of 8148 CHC adults were selected. Cardiovascular events (stroke, acute coronary syndrome, pulmonary embolism, heart failure, arrhythmias and conduction disorders [ACD], peripheral arterial disease [PAD]) and extrahepatic solid cancers were derived from the SNDS. Associations between DAAs and extrahepatic events were estimated using marginal structural models, with adjustments for clinical confounders.Results: Analyses of 12 905 person-years of no DAA exposure and 22 326 person-years following DAA exposure showed a decreased risk of PAD after DAA exposure (hazard ratio [HR], 0.54; 95% CI, 0.33–0.89), a beneficial effect of DAAs on overall cardiovascular outcomes in patients with advanced fibrosis (aHR, 0.58; 95% CI, 0.42–0.79), and an increased risk of ACD (hazard ratio [HR], 1.46; 95% CI, 1.04–2.04), predominant after the first year following DAA initiation. There was no association between DAAs and extrahepatic cancer risk (HR, 1.23; 95% CI, 0.50–3.03).Conclusions: DAAs were not associated with extrahepatic cancer development or reduction. They were associated with a decreased risk of PAD and an increased risk of ACD, supporting long-term cardiac monitoring after DAA therapy.

Published
2022

140. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)

Author

Nahon, Pierre, Lescat, Mathilde, Layese, Richard, Bourcier, Valérie, Talmat, Nabila, Allam, Setty, Marcellin, Patrick, Guyader, Dominique, Pol, Stanislas, Larrey, Dominique, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Roulot, Dominique, Tran, Albert, Bronowicki, Jean-Pierre, Zarski, Jean-Pierre, Goria, Odile, Calès, Paul, Péron, Jean-Marie, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Blanc, Jean-Frédéric, Abergel, Armand, Serfaty, Lawrence, Mallat, Ariane, Grangé, Jean-Didier, Attali, Pierre, Bacq, Yannick, Wartelle, Claire, Dao, Thông, Benhamou, Yves, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Capron, Dominique, Bernard-Chabert, Brigitte, Hillaire, Sophie, Di Martino, Vincent, Trinchet, Jean-Claude, Moreau, Richard, Roudot-Thoraval, Françoise, Kempf, Marie, Bert, Fréderic, Doloy, Alexandra, Poilane, Isabelle, Peuchant, Olivia, Carbonnelle, Etienne, Picard, Bertrand, Burucoa, Christophe, Cattoir, Vincent, Decré, Dominique, Degand, Nicolas, Dortet, Laurent, Kayal, Samer, Vernet-Garnier, Véronique, Lozniewski, Alain, Tuaillon, Edouard, Vimont, Sophie, Bessède, Emilie, Patry, Isabelle, Lemaitre, Nadine, and Pachetii, Christine

Published
2017
Full Text
View/download PDF

143. Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection

Author

Patin, Etienne, Kutalik, Zoltán, Guergnon, Julien, Bibert, Stéphanie, Nalpas, Bertrand, Jouanguy, Emmanuelle, Munteanu, Mona, Bousquet, Laurence, Argiro, Laurent, Halfon, Philippe, Boland, Anne, Müllhaupt, Beat, Semela, David, Dufour, Jean–François, Heim, Markus H., Moradpour, Darius, Cerny, Andreas, Malinverni, Raffaele, Hirsch, Hans, Martinetti, Gladys, Suppiah, Vijayaprakash, Stewart, Graeme, Booth, David R., George, Jacob, Casanova, Jean–Laurent, Bréchot, Christian, Rice, Charles M., Talal, Andrew H., Jacobson, Ira M., Bourlière, Marc, Theodorou, Ioannis, Poynard, Thierry, Negro, Francesco, Pol, Stanislas, Bochud, Pierre–Yves, and Abel, Laurent

Published
2012
Full Text
View/download PDF

144. Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort.

Author

Lam, Laurent, Fontaine, Hélène, Lapidus, Nathanael, Bellet, Jonathan, Lusivika‐Nzinga, Clovis, Nicol, Jérôme, Dorival, Céline, Cagnot, Carole, Hejblum, Gilles, Pol, Stanislas, Bourlière, Marc, and Carrat, Fabrice

Subjects
CHRONIC hepatitis B, HEALTH insurance claims, HEPATIC fibrosis, CLINICAL pathology, NATIONAL health insurance
Abstract

The validity of algorithms for identifying patients with chronic hepatitis B or C virus (HBV or HCV) infection in claims databases has been little explored. The performance of 15 algorithms was evaluated. Data from HBV‐ or HCV‐infected patients enrolled between August 2012 and December 2015 in French hepatology centres (ANRS CO22 HEPATHER cohort) were individually linked to the French national health insurance system (SNDS). The SNDS covers 99% of the French population and contains healthcare reimbursement data. Performance metrics were calculated by comparing the viral status established by clinicians with those obtained with the algorithms identifying chronic HBV‐ and HCV‐infected patients. A total of 14 751 patients (29% with chronic HBV and 63% with chronic HCV infection) followed‐up until December 2018 were selected. Despite good specificity, the algorithms relying on ICD‐10 codes performed poorly. By contrast, the multi‐criteria algorithms combining ICD‐10 codes, antiviral dispensing, laboratory diagnostic tests (HBV DNA or HCV RNA detection and quantification, HCV genotyping), examinations for the assessment of liver fibrosis and long‐term disease registrations were the most effective (sensitivity 0.92, 95% CI, 0.91–0.93 and specificity 0.96, 95% CI, 0.95–0.96 for identifying chronic HBV‐infected patients; sensitivity 0.94, 95% CI, 0.94–0.94 and specificity 0.85, 95% CI, 0.84–0.86 for identifying chronic HCV‐infected patients). In conclusion, the multi‐criteria algorithms perform well in identifying patients with chronic hepatitis B or C infection and can be used to estimate the magnitude of the public health burden associated with hepatitis B and C in France. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

145. Резюме клінічної практики KDIGO 2022 щодо профілактики, діагностики, оцінки й лікування гепатиту С при хронічній хворобі нирок.

Author

Martin, Paul, Awan, Ahmed A., Berenguer, Marina C., Bruchfeld, Annette, Fabrizi, Fabrizio, Goldberg, David S., Jia, Jidong, Kamar, Nassim, Mohamed, Rosmawati, Pessôa, Mário Guimarães, Pol, Stanislas, Sise, Meghan E., Balk, Ethan M., Gordon, Craig E., Adam, Gaelen, Cheung, Michael, Earley, Amy, and Jadoul, Michel

Subjects
HEPATITIS C treatment, CHRONIC kidney failure
Published
2023
Full Text
View/download PDF

147. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

Author

Pol, Stanislas, Ghalib, Reem H, Rustgi, Vinod K, Martorell, Claudia, Everson, Greg T, Tatum, Harvey A, Hézode, Christophe, Lim, Joseph K, Bronowicki, Jean-Pierre, Abrams, Gary A, Bräu, Norbert, Morris, David W, Thuluvath, Paul J, Reindollar, Robert W, Yin, Philip D, Diva, Ulysses, Hindes, Robert, McPhee, Fiona, Hernandez, Dennis, Wind-Rotolo, Megan, Hughes, Eric A, and Schnittman, Steven

Published
2012
Full Text
View/download PDF

149. Reply to: “Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: A case control study from the prospective COVID-ICU database”

Author

Depret, François, primary, Bouam, Samir, additional, Schwarzinger, Michaël, additional, Mallet, Vincent, additional, Depret, François, additional, Fontaine, Hélène, additional, Corouge, Marion, additional, Pichard, Anaïs Vallet, additional, Hollande, Clémence, additional, Sogni, Philippe, additional, and Pol, Stanislas, additional

Published
2022
Full Text
View/download PDF

150. Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort)

Author

Barré, Tangui, primary, Fontaine, Hélène, additional, Ramier, Clémence, additional, Di Beo, Vincent, additional, Pol, Stanislas, additional, Carrieri, Patrizia, additional, Marcellin, Fabienne, additional, Cagnot, Carole, additional, Dorival, Céline, additional, Zucman-Rossi, Jessica, additional, Zoulim, Fabien, additional, Carrat, Fabrice, additional, and Protopopescu, Camelia, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results